| Literature DB >> 34816367 |
Zhao Cheng1, Asif Johar1, Magnus Nilsson2,3, Pernilla Lagergren4,5.
Abstract
BACKGROUND: The impact of postoperative complications on cancer-related fatigue is unknown. This nationwide prospective cohort study aimed to assess the trajectory of cancer-related fatigue and the influence of predefined postoperative complications on cancer-related fatigue up to 2 years after esophageal cancer surgery.Entities:
Mesh:
Year: 2021 PMID: 34816367 PMCID: PMC8989940 DOI: 10.1245/s10434-021-11049-z
Source DB: PubMed Journal: Ann Surg Oncol ISSN: 1068-9265 Impact factor: 5.344
Postoperative complications within 30 days after esophagectomy for esophageal cancer for 331 patients
| Complication | Definition | |
|---|---|---|
| Complications | Occurrence of any complications | |
| No | 120 (36.3) | |
| Yes | 211 (63.7) | |
| Clavien-Dindo classification | – | |
| 0–1 | 129 (39.0) | |
| 2–3a | 116 (35.0) | |
| 3b–4 | 85 (25.7) | |
| Missing | 1 (0.3) | |
| Complication groupa | ||
| Medical complication | Sepsis, pneumonia, hepatic insufficiency, renal failure, deep venous thrombosis, pulmonary embolism, other embolism, myocardial infarction, atrial fibrillation, cerebral infarction, or respiratory insufficiency | 146 (44.1) |
| Surgical complication | Postoperative bleeding, anastomotic insufficiency, substitute necrosis, thoracic ductus injury, intrathoracic abscess or empyema, intra-abdominal abscess, wound infection, wound dehiscence, ileus, gastric perforation, recurrent laryngeal nerve paralysis, or strictures in anastomosis | 112 (33.8) |
| Pulmonary complication | Respiratory insufficiency or pneumonia | 97 (29.3) |
| Cardiac complication | Myocardial infarction or atrial fibrillation | 61 (18.4) |
| Complications typea | ||
| Pneumonia | Radiologically detected infiltrate with clinical symptoms such as fever, cough, or dyspnea | 65 (19.6) |
| Atrial fibrillation | Newly electrocardiogram detected and treatment required | 57 (17.2) |
| Anastomotic insufficiency | Clinically significant or radiologically detected | 54 (16.3) |
| Respiratory insufficiency | Reintubation or mechanical ventilation needed | 52 (15.7) |
| Sepsis | Causing clinical symptoms such as fever, chills, and proven bacteria in the blood | 34 (10.3) |
| Wound infection | Causing clinical symptoms and requiring treatment | 25 (7.6) |
| Intrathoracic abscess or empyema | ≥3*3 cm radiologically or surgically detected abscess with clinical symptoms such as fever, pain or dyspnea | 22 (6.6) |
| Recurrent laryngeal nerve paralysis | Laryngeal inspection ascertained | 20 (6.0) |
| Pulmonary embolism | Radiologically detected | 15 (4.5) |
| Thoracic ductus injury | Thoracic lymph leakage requiring drainage for more than 7 days or reoperation | 15 (4.5) |
| Substitute necrosis | Clinically significant ischemia with ulceration or perforation | 11 (3.3) |
| Intra-abdominal abscess | ≥3*3cm radiologically or surgically detected abscess with clinical symptoms such as fever or pain | 7 (2.1) |
| Myocardial infarction | Electrocardiogram or cardiac enzymes verified | 7 (2.1) |
| Ileus | Radiologically detected ileus in need of surgery | 5 (1.5) |
| Renal failure | Dialysis needed | 4 (1.2) |
| Postoperative bleeding | >2000 ml or requiring reoperation | 2 (0.6) |
| Other embolism | Radiologically detected and requiring treatment | 2 (0.6) |
| Strictures in anastomosis | Endoscopic intervention required | 2 (0.6) |
| Hepatic insufficiency | Progressive jaundice | 1 (0.3) |
| Gastric perforation | Surgical intervention required | 1 (0.3) |
| Wound dehiscence | Clinically obvious wound rupture | 0 (0.0) |
| Deep venous thrombosis | Radiologically or clinically verified with treatment needs | 0 (0.0) |
| Cerebral infarction/stroke | Radiologically verified | 0 (0.0) |
| Other complicationsb | – | 38 (11.5) |
aEach patient could have more than 1 group or type of complications
bMost of the patients who had other complications also had the specific complication types listed above
Demographics and clinical characteristics of the 331 patients who underwent esophagectomy for esophageal cancer in Sweden
| Complication | ||
|---|---|---|
| No | Yes | |
| Total | 120 (36.3) | 211 (63.7) |
| Age at operation | ||
| Mean | 66.5 ± 8.0 | 67.3 ± 8.6 |
| Sex | ||
| Male | 14 (11.7) | 20 (9.5) |
| Female | 106 (88.3) | 191 (90.5) |
| Education level (years) | ||
| < 9 | 26 (21.7) | 49 (23.2) |
| 9–12 | 51 (42.5) | 83 (39.3) |
| > 12 | 29 (24.2) | 56 (26.6) |
| Missing | 14 (11.6) | 23 (10.9) |
| Weight loss (kg) | ||
| Mean | 8.8 ± 7.8 | 9.4 ± 8.8 |
| Missing | 3 (0.03) | 13 (0.06) |
| Pathologic tumor stage | ||
| 0–1 | 42 (35.0) | 69 (32.7) |
| 2 | 40 (33.3) | 68 (32.3) |
| 3–4 | 38 (31.7) | 72 (34.1) |
| Missing | 0 (0.0) | 2 (0.9) |
| Neoadjuvant therapy | ||
| No | 99 (82.5) | 158 (74.9) |
| Yes | 19 (15.8) | 49 (23.2) |
| Missing | 2 (1.7) | 4 (1.9) |
| Tumor histology | ||
| Adenocarcinoma | 105 (87.5) | 172 (81.5) |
| Squamous cell carcinoma | 15 (12.5) | 39 (18.5) |
| Charlson comorbidity index | ||
| 0 | 60 (50.0) | 84 (39.8) |
| 1 | 38 (31.7) | 71 (33.7) |
| ≥ 2 | 22 (18.3) | 56 (26.5) |
Fig. 1QLQ-C30 fatigue trajectories and mean score differences with 95% confidence intervals between time points by predefined complications
Fig. 2QLQ-FA12 fatigue trajectories and mean score differences with 95% confidence intervals between time points by predefined complication.
Adjusted mean score differences with 95 % confidence intervals in QLQ-C30 and QLQ-FA12 fatigue scores between patients with and without predefined medical complications after esophagectomy at different time pointsa
| QLQ-C30 fatigue | QLQ-FA12 fatigue | |||||
|---|---|---|---|---|---|---|
| 1 Year | 1.5 Years | 2 Years | 1 Year | 1.5 Years | 2 Years | |
| Complications | ||||||
| No | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes | 1.0 (−4.9 to 6.8) | 5.6 (−0.7 to 12.0) | 3.1 (−3.6 to 9.8) | 1.4 (−3.2 to 6.0) | 2.2 (−2.9 to 7.4) | |
| Clavien-Dindo classification | ||||||
| 0–1 | Reference | Reference | Reference | Reference | Reference | Reference |
| 2–3a | − 1.4 (− 7.9 to 5.1) | 4.7 (− 2.3 to 11.6) | 1.6 (−5.8 to 9.0) | 0.6 (−4.5 to 5.7) | 5.4 (−0.0 to 10.8) | 0.6 (−5.1 to 6.3) |
| 3b–4 | 5.3 (−2.0 to 12.5) | 5.6 (−2.7 to 13.8) | 2.0 (−3.7 to 7.7) | 5.4 (−0.7 to 11.5) | 5.0 (−1.4 to 11.4) | |
| Surgical complication | ||||||
| No | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes | −0.7 (−6.8 to 5.3) | −3.1 (−9.7 to 3.5) | −3.8 (−10.9 to 3.2) | −2.5 (−7.3 to 2.3) | −2.8 (−7.9 to 2.3) | −2.6 (−8.1 to 2.8) |
| Medical complication | ||||||
| No | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes | 0.4 (−5.3 to 6.1) | 5.4 (−0.7 to 11.5) | 3.3 (−3.2 to 9.8) | 0.7 (−3.8 to 5.1) | 2.8 (−2.2 to 7.8) | |
| Pulmonary complication | ||||||
| No | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes | 0.3 (−5.9 to 6.5) | 4.2 (−2.5 to 10.8) | 3.0 (−4.0 to 10.0) | 0.3 (−4.6 to 5.2) | 1.9 (−3.5 to 7.3) | |
| Cardiac complication | ||||||
| No | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes | −1.6 (−9.3 to 6.1) | 4.6 (−3.6 to 12.8) | −1.3 (−10.1 to 7.5) | −1.1 (−7.2 to 5.0) | 0.6 (−5.8 to 7.0) | 0.6 (−6.2 to 7.4) |
aValues in bold are both clinically relevant and statistically significant